Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tinzaparin.

Nina N Wong1

  • 1Department of Pharmacy and Family Medicine, Montefiore Medical Center, Bronx, New York 10467, USA. nwong@montefiore.org

Heart Disease (Hagerstown, Md.)
|September 28, 2002
PubMed
Summary
This summary is machine-generated.

Tinzaparin, a low-molecular-weight heparin (LMWH), is effective for treating deep vein thrombosis and preventing blood clots in surgical patients. It demonstrates comparable efficacy to unfractionated heparin (UFH) with a reduced risk of bleeding events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fondaparinux: a synthetic selective factor-Xa inhibitor.

Heart disease (Hagerstown, Md.)ยท2003
See all related articles

Area of Science:

  • Pharmacology
  • Thrombosis Management
  • Medical Therapeutics

Background:

  • Low-molecular-weight heparins (LMWH) present clinical and economic benefits over unfractionated heparin (UFH).
  • Tinzaparin is an approved LMWH for deep venous thrombosis (DVT) and pulmonary embolism (PE) treatment, often with warfarin.
  • Existing data support tinzaparin's efficacy in DVT/PE and surgical thromboembolism prophylaxis.

Purpose of the Study:

  • To review the efficacy and safety of tinzaparin in various clinical settings.
  • To compare tinzaparin's performance against unfractionated heparin (UFH).
  • To identify current limitations and data gaps for tinzaparin use.

Main Methods:

  • Review of clinical studies and trial data involving tinzaparin.

Related Experiment Videos

  • Comparative analysis of tinzaparin versus UFH in treated patients.
  • Assessment of adverse events, particularly bleeding complications.

    • Main Results:

    • Tinzaparin demonstrated at least equivalent efficacy to UFH in treating DVT/PE.
    • Fewer adverse bleeding events were observed with tinzaparin compared to UFH.
    • Tinzaparin is effective for thromboembolic prophylaxis in surgical patients and those at risk.

    Conclusions:

    • Tinzaparin is a viable and safe alternative to UFH for DVT/PE and surgical prophylaxis.
    • Current evidence suggests caution regarding its use in ischemic stroke patients.
    • Further research is needed to establish its role in unstable angina and non-ST-segment elevation myocardial infarction.